Safety and Tolerability of PCD in Patients With Larynx SCC -- Number of Adverse Events
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer · Source last updated 2026-03-09
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
adverse events
Interval / dispersion
Not reported
Time frame
first administration of investigational agent until 30 days following last dose of study drug; approximately 3 years and 11 months
What was measured
Adverse events (AEs) are categorized as follows: Treatment-Emergent Adverse Events (TEAEs), which refer to any AEs that arise or worsen in severity after the initiation of treatment with the study product; and Treatment-Related Adverse Events (TRAEs), defined as TEAEs that are considered possibly, probably, or definitely related to the treatment. Adverse Events were graded 1 to 5 via CTAE 4.0 guidelines. All AEs, whether serious or non-serious, will be captured from the time of the first administration of the investigational agent until 30 days following the last dose of study drug or until the initiation of alternative anticancer therapy
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Experimental (Cis/Doce/Pembro)
24
Reported measurements
Grade 4 : Definite
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
0
Not reported
Not reported
Not reported
Not reported
Grade 4 : Probable
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
3
Not reported
Not reported
Not reported
Not reported
Grade 4 : Possible
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
0
Not reported
Not reported
Not reported
Not reported
Grade 4 : Unlikely
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
0
Not reported
Not reported
Not reported
Not reported
Grade 4 : Unrelated
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
0
Not reported
Not reported
Not reported
Not reported
Grade 3 : Definite
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
3
Not reported
Not reported
Not reported
Not reported
Grade 3 : Probable
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
3
Not reported
Not reported
Not reported
Not reported
Grade 3 : Possible
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
2
Not reported
Not reported
Not reported
Not reported
Grade 3 : Unlikely
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
2
Not reported
Not reported
Not reported
Not reported
Grade 3 : Unrelated
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
7
Not reported
Not reported
Not reported
Not reported
Grade 2 : Definite
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
12
Not reported
Not reported
Not reported
Not reported
Grade 2 : Probable
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
28
Not reported
Not reported
Not reported
Not reported
Grade 2 : Possible
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
20
Not reported
Not reported
Not reported
Not reported
Grade 2 : Unlikely
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
5
Not reported
Not reported
Not reported
Not reported
Grade 2 : Unrelated
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
19
Not reported
Not reported
Not reported
Not reported
Grade 1 : Definite
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
16
Not reported
Not reported
Not reported
Not reported
Grade 1 : Probable
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
74
Not reported
Not reported
Not reported
Not reported
Grade 1 : Possible
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
128
Not reported
Not reported
Not reported
Not reported
Grade 1 : Unlikely
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
33
Not reported
Not reported
Not reported
Not reported
Grade 1 : Unrelated
Values in adverse events · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Experimental (Cis/Doce/Pembro)
104
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
0
title
Grade 4 : Definite
categories
measurements
group Id
OG000
value
3
title
Grade 4 : Probable
categories
measurements
group Id
OG000
value
0
title
Grade 4 : Possible
categories
measurements
group Id
OG000
value
0
title
Grade 4 : Unlikely
categories
measurements
group Id
OG000
value
0
title
Grade 4 : Unrelated
categories
measurements
group Id
OG000
value
3
title
Grade 3 : Definite
categories
measurements
group Id
OG000
value
3
title
Grade 3 : Probable
categories
measurements
group Id
OG000
value
2
title
Grade 3 : Possible
categories
measurements
group Id
OG000
value
2
title
Grade 3 : Unlikely
categories
measurements
group Id
OG000
value
7
title
Grade 3 : Unrelated
categories
measurements
group Id
OG000
value
12
title
Grade 2 : Definite
categories
measurements
group Id
OG000
value
28
title
Grade 2 : Probable
denoms
counts
group Id
OG000
value
24
units
Participants
description
Adverse events (AEs) are categorized as follows: Treatment-Emergent Adverse Events (TEAEs), which refer to any AEs that arise or worsen in severity after the initiation of treatment with the study product; and Treatment-Related Adverse Events (TRAEs), defined as TEAEs that are considered possibly, probably, or definitely related to the treatment. Adverse Events were graded 1 to 5 via CTAE 4.0 guidelines. All AEs, whether serious or non-serious, will be captured from the time of the first administration of the investigational agent until 30 days following the last dose of study drug or until the initiation of alternative anticancer therapy
Triangle